Pembrolizumab with Paclitaxel for PD-L1-Positive Platinum-Resistant Ovarian Cancer: What Changed After FDA Approval
There is important news for patients with platinum-resistant ovarian cancer. In February 2026, the FDA approved pembrolizumab in combination with paclitaxel for patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer if the tumor expresses PD-L1 ≥1 and 1-2 lines of systemic therapy have already been given.
The KEYNOTE-B96 Study
The basis for approval was the KEYNOTE-B96 study. It enrolled 643 patients with platinum-resistant disease after at least one line of platinum-containing chemotherapy. Progression had to be confirmed within 6 months of the last platinum dose. Patients were randomized to pembrolizumab plus paclitaxel with or without bevacizumab, or placebo plus paclitaxel with or without bevacizumab.
The key practical finding concerns patients with PD-L1-positive tumors, i.e., with CPS ≥1. In this group, median progression-free survival was 8.3 months versus 7.2 months in the control group, and median overall survival reached 18.2 months versus 14.0 months. This corresponds to a 24% reduction in the risk of death (HR 0.76; p=0.0053). The reduction in risk of progression or death was 28% (HR 0.72; p=0.0014).
Why is this truly important for practice? In the setting of platinum-resistant recurrence after 1-2 lines of treatment, therapeutic decisions are almost always made very carefully. And the emergence of a new approved option for PD-L1-positive patients is significant in itself.
When to Seek a Repeat Consultation
- you have been told that the disease has become platinum-resistant and you need to choose the next line of treatment
- you have already had 1-2 lines of therapy and want to understand whether pembrolizumab should be discussed
- PD-L1 has not been tested or the result raises questions
- you are being offered different treatment options and need clear decision logic
- you want to evaluate not just the next regimen but the entire further treatment strategy
What to Prepare Before Your Consultation
For a thorough review, it is best to prepare in advance discharge summaries from all lines of treatment, the pathology report, immunohistochemistry and molecular test results, a description of the timing of platinum response, recent CT or MRI, and data on tolerability of previous therapy.
Conclusion
The approval of pembrolizumab with paclitaxel, with or without bevacizumab, adds a new option for patients with PD-L1-positive platinum-resistant ovarian cancer after 1-2 lines of therapy. But the clinical value of this news lies elsewhere. Now it is even more important to accurately determine who truly benefits from this regimen and who would be better served by a different plan.
Frequently Asked Questions
Who is eligible for pembrolizumab with paclitaxel for ovarian cancer?
Based on the scientific data, this applies to adult patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer if the tumor is PD-L1-positive and 1-2 lines of systemic therapy have already been given.
Is PD-L1 testing required before discussing this regimen?
Yes. The FDA simultaneously approved the PD-L1 22C3 test for patient selection. This test is performed using immunohistochemistry.
Did the regimen actually improve overall survival?
Yes, in patients with CPS ≥1, median overall survival in the KEYNOTE-B96 study was 18.2 months versus 14.0 months in the control group.
Is pembrolizumab given only with paclitaxel?
In the FDA-approved indication, it refers to the combination with paclitaxel, with or without bevacizumab.
Can I change my treatment on my own after this news?
No. Such decisions require an assessment of platinum-resistant status, treatment history, PD-L1 status, comorbidities, and tolerability of previous therapy.
More answers on the FAQ page.